本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Inhibrx Biosciences

109.27
-2.1500-1.93%
盤後109.270.00000.00%19:30 EDT
成交量:21.10萬
成交額:2,341.92萬
市值:16.03億
市盈率:-12.31
高:115.11
開:113.00
低:108.93
收:111.42
52周最高:155.29
52周最低:26.19
股本:1,467.12萬
流通股本:863.89萬
量比:0.35
換手率:2.44%
股息:- -
股息率:- -
每股收益(TTM):-8.8768
每股收益(LYR):-9.0434
淨資產收益率:-1773.60%
總資產收益率:-43.61%
市淨率:-30.26
市盈率(LYR):-12.08

資料載入中...

2024/11/04

重要事件披露

Form 8-K - Current report
2024/08/13

重要事件披露

Form 8-K - Current report
2024/08/13

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/06/17

重要事件披露

Form 8-K - Current report
2024/06/15

SEC問詢函

Form CORRESP - Correspondence
2024/06/11

招股説明書

Form S-1 - General form for registration of securities under the Securities Act of 1933
2024/06/07

超過5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2024/06/03

超過5%披露

Form SC 13D - General statement of acquisition of beneficial ownership
2024/06/03

超過5%披露

Form SC 13D - General statement of acquisition of beneficial ownership
2024/06/03

超過5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/05/31

超過5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2024/05/30

員工持股計劃

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/05/30

員工持股計劃

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/05/30

員工持股計劃

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/05/30

員工持股計劃

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/05/30

重要事件披露

Form 8-K - Current report
2024/05/30

交易所摘牌聲明

Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
2024/05/29

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/05/24

重要事件披露

Form 8-K - Current report
2024/05/23

SEC問詢函

Form CORRESP - Correspondence